DEPARTMENT OF PEDIATRICS – DIVISION OF TRANSLATIONAL THERAPEUTICS
Do you want to make a difference to children? If being part of a multi-disciplinary team that pursues excellence in research, bridges clinical practice and leads educational endeavours through innovative strategies sounds appealing to you, this is the place you want to be.
The Division of Translational Therapeutics under the leadership of Dr. Bruce Carleton, and based at the Child & Family Research Institute (CFRI) in Vancouver, BC is seeking trainees in the areas of drug safety, drug effectiveness and drug policy.
We are committed to studying and evaluating drug therapies with the goal of improving human health and quality of life through two specific areas of drug research:
- Drug Safety (Pharmacogenomics / Adverse Drug Reactions)
Candidates will lead research projects that use state of the art genotyping and sequencing platforms to identify the genetic determinants of severe adverse drug reactions (ADRs) in paediatric and adult populations. In close collaboration with the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) and its active surveillance network, genetic association and validation studies will be performed to define ADR causal genes and to develop diagnostic tests to offer personalized therapeutic recommendations for commonly used drugs. Current pharmacogenomics and surveillance focuses are: cisplatin, anthracyclines, vincristine, warfarin, codeine, inhaled corticosteroids, 5-HT3 antagonists (antiemetics), and drugs used in the treatment of Hepatitis C. Other projects include the development of clinical practice guidelines for six drugs, and knowledge translation to implement pharmacogenetic testing in clinical practice.
- Drug Effectiveness and Cost Management (Population Therapeutics / Pharmacoepidemiology)
This research area focuses on medication use and healthcare outcomes by employing population-based datasets. The main goal is to foster pharmaceutical policy innovation through proactive policy research, training and knowledge translation concerning the effectiveness, safety and cost management of prescription drugs. Current studies include: identifying the burden of paediatric asthma in British Columbia, evaluating methods to prevent asthma-related Emergency Department visits, and a number of studies which are being conducted in collaboration with the BC Provincial Health Services Authority (PHSA) evaluating prostate cancer survival rates of men in British Columbia who receive calcium-channel blockers, and studying cardiovascular and ocular adverse events associated with bevacizumab and ranibizumab in the treatment of age-related macular degeneration.
As one of the leading research centers in Canada, trainees will be exposed to both the innovative research at the Child & Family Research Institute (CFRI) and the strong academic environment of the University of British Columbia. In these stimulating and complementary surroundings, trainees will have many opportunities for advancement and interdisciplinary professional development.
Applicants with a background in pharmacogenomics, clinical pharmacology, medical genetics, experimental medicine, pediatrics, pharmacoepidemiology, biostatistics, bioinformatics, population health, pharmacy, medical anthropology, ethics or any other related fields are encouraged to apply. If interested, please submit a cover letter detailing research interests, curriculum vitae, writing sample and three references to:
Gabriella Groeneweg, MA
Administration and Strategic Communications, Manager